Renal biomarkers of kidney injury in cardiorenal syndrome

被引：19

作者：

Comnick M. ^{[1
]}

Ishani A. ^{[2
]}

机构：

[1] Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN 55414, 717 Delaware Street, Southeast

[2] Minneapolis VA Health Care System, Minneapolis, MN 55417

来源：

Current Heart Failure Reports | 2011年 / 8卷 / 2期

关键词：

Acute kidney injury; Albuminuria; Cardiorenal syndrome; Cystatin C; Epidemiology; Heart failure; Kidney injury molecule-1; N-Acetyl-β-D-Glucosaminidase; Neutrophil gelatinase-associated lipocalin; NGAL;

D O I：

10.1007/s11897-011-0052-x

中图分类号：

学科分类号：

摘要：

The cardiorenal syndromes comprise a group of disorders in which impairment of either the heart or the kidney results in injury to the other. Although the pathophysiology is not yet well understood, the clinical consequences are increasingly recognized. In congestive heart failure, the development of worsening renal function is associated with increased hospitalizations and death. Urinary biomarkers offer a rapid and noninvasive method for detecting kidney injury. The role of urinary biomarkers such as neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, N-acetyl-β-D- glucosaminidase, interleukin-18, and cystatin C are being investigated to provide diagnostic, prognostic, and, eventually, therapeutic information. This article reviews the utility of urinary biomarkers in congestive heart failure and explores directions for future research. © 2011 Springer Science+Business Media, LLC (outside the USA).

引用

页码：99 / 105

页数：6

共 59 条

[1] Roger V.L., Go A.S., Lloyd-Jones D.M., Et al., Heart disease and stroke statistics-2010 update: A report from the American Heart Association, Circulation, 121, pp. 46-214, (2010)
[2] Ronco C., McCullough P., Anker S.D., Et al., Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative, Eur Heart J, 31, pp. 703-11, (2010)
[3] Sarraf M., Masoumi A., Schrier R., Cardiorenal syndrome in acute decompensated heart failure, CJASN, 4, pp. 2013-26, (2009)
[4] Stenvinkel P., Carrero J.J., Axelson J., Et al., Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?, CJASN, 3, pp. 505-21, (2008)
[5] Gottlieb S.S., Abraham W., Butler J., Forman D.E., Loh E., Massie B.M., O'Connor C.M., Rich M.W., Stevenson L.W., Young J., Krumholz H.M., The prognostic importance of different definitions of worsening renal function in congestive heart failure, Journal of Cardiac Failure, 8, 3, pp. 136-141, (2002)
[6] Damman K., Deursen V.M., Navis G., Et al., Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease, J Am Coll Cardiol, 53, pp. 582-8, (2009)
[7] Damman K., Voors A.A., Hillege H.L., Et al., Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality, Eur J of Heart Fail, pp. 1-9, (2010)
[8] Nohria A., Hasselblad V., Stebbins A., Pauly D.F., Fonarow G.C., Shah M., Yancy C.W., Califf R.M., Stevenson L.W., Hill J.A., Cardiorenal interactions insights from the ESCAPE trial, Journal of the American College of Cardiology, 51, 13, pp. 1268-1274, (2008)
[9] Mullens W., Abrahams Z., Francis G.S., Et al., Importance of venous congestion for worsening of renal function in advanced decompensated heart failure, J Am Coll Cardiol, 53, pp. 589-96, (2009)
[10] Knight E.L., Glynn R.J., McIntyre K.M., Mogun H., Avorn J., Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the Studies of Left Ventricular Dysfunction (SOLVD), American Heart Journal, 138, 5 I, pp. 849-855, (1999)

← 1 2 3 4 5 6 →